Evidence map›Paper›PMID 32807798›Full record

ArticleNature communications2020

Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease.

Xu Zhang, Zhibin Ning, Janice Mayne, Yidai Yang, Shelley A Deeke, Krystal Walker, Charles L Farnsworth, Matthew P Stokes, Jean-François Couture, David Mack and 2 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Xu ZhangShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.ORCID http://orcid.org/0000-0003-2406-9478
Zhibin NingShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
Janice MayneShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
Yidai YangShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
Shelley A DeekeShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
Krystal WalkerShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
Charles L FarnsworthCell Signaling Technology Inc., Danvers, MA, 01923, USA.
Matthew P StokesCell Signaling Technology Inc., Danvers, MA, 01923, USA.
Jean-François CoutureShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada.
David MackDepartment of Pediatrics, Faculty of Medicine, University of Ottawa and Children's Hospital of Eastern Ontario Inflammatory Bowel Disease Centre and Research Institute, Ottawa, ON, K1H 8L1, Canada.
Alain StintziShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada. astintzi@uottawa.ca.ORCID http://orcid.org/0000-0003-3728-4038
Daniel FigeysShanghai Institute of Materia Medica-University of Ottawa Joint Research Center in Systems and Personalized Pharmacology, University of Ottawa, Ottawa, ON, K1H 8M5, Canada. dfigeys@uottawa.ca.ORCID http://orcid.org/0000-0002-5373-7546
University of Ottawa · CACell Signaling Technology (United States) · US

Funding

CIHR GPH-129340CIHR MOP-114872
6 · The paper itself

Abstract

Lysine acetylation (Kac), an abundant post-translational modification (PTM) in prokaryotes, regulates various microbial metabolic pathways. However, no studies have examined protein Kac at the microbiome level, and it remains unknown whether Kac level is altered in patient microbiomes. Herein, we use a peptide immuno-affinity enrichment strategy coupled with mass spectrometry to characterize protein Kac in the microbiome, which successfully identifies 35,200 Kac peptides from microbial or human proteins in gut microbiome samples. We demonstrate that Kac is widely distributed in gut microbial metabolic pathways, including anaerobic fermentation to generate short-chain fatty acids. Applying to the analyses of microbiomes of patients with Crohn's disease identifies 52 host and 136 microbial protein Kac sites that are differentially abundant in disease versus controls. This microbiome-wide acetylomic approach aids in advancing functional microbiome research.

Indexed as

AcetylationCrohn DiseaseGastrointestinal MicrobiomeHealthy VolunteersHumansLysineMultivariate AnalysisProteomicsTandem Mass SpectrometryLysine

Identifiers

PMID32807798
PMCPMC7431864
OpenAlexW3049003747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.